Affiliation:
1. Internal Medicine Department, Medicine Faculty Federal University of Goiás Goiás Brazil
2. Clinical Medicine Department, Medical and Life School Pontifical Catholic University of Goiás Goiás Brazil
3. Clinical Medicine Department, Medical School Evangelical University of Goiás Goiás Brazil
Abstract
AbstractBackgroundRadiofrequency catheter ablation (RFCA) has emerged as a therapeutic option for surgical myectomy and alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM), but its efficacy remains unclear.AimDue to limited research on RFCA for HCM, there is an ongoing attempt to assess its efficacy and safety.MethodsPubMed, Embase, and Scopus were systematically searched for studies assessing the efficacy outcomes for patients with HOCM who underwent RFCA. Mean differences (MDs) with 95% confidence intervals (CIs) were computed using a random‐effects model and heterogeneity was assessed using I2 statistics.ResultsWe included 11 studies comprising 470 patients, of whom 34.6% were female. The mean patient age ranged from 43.7 to 60.7 years. During the follow‐up after RFCA, there was a significant decrease in the left ventricular outflow tract (LVOT) gradient at rest (MD −60.25 mmHg; 95% CI [−70.53;−59.14 mmHg]; p < 0.01) and during stimulation (MD −83.56 mmHg; 95% CI [−100.36;−66.76 mmHg]; p < 0.01). Moreover, RFCA reduced interventricular septum (IVS) thickness (MD −3.61 mm; 95% CI [−5.64; −1.59 mm]; p = 0.01) and New York Heart Association (NYHA) class (MD −1.46; 95% CI [−1.69; −1.24]; p < 0.01).ConclusionsIn patients with HOCM, RFCA was associated with an improved NYHA class, reduced IVS thickness, and decreased LVOT gradient at rest and with stimulation.